Artiva Biotherapeutics (ARTV) FCF Margin (2023 - 2024)

Artiva Biotherapeutics' (ARTV) quarterly FCF Margin came in at 6015.54% in Q1 2024, down 1686.27% on a QoQ basis from 336.77% in Q4 2023.

Artiva Biotherapeutics (ARTV) FCF Margin (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of FCF Margin data on file, last reported at 6015.54% in Q1 2024.

On a quarterly basis, FCF Margin changed N/A year-over-year to 6015.54% in Q1 2024; TTM through Dec 2024 was 21947.81%, a N/A change from a year earlier, with the FY2024 full-year figure at 21947.81%, down 2180661.0% from the prior year.
FCF Margin for Q1 2024 stood at 6015.54%, down from 336.77% in the prior quarter.
Over the last five years, FCF Margin for ARTV reached as high as 50.39% in Q3 2023 and fell as low as 6015.54% in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Artiva Biotherapeutics	249.99 Mn	249.99 Mn	-	-

Download Data